BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 7909277)

  • 1. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer.
    Ebina M; Steinberg SM; Mulshine JL; Linnoila RI
    Cancer Res; 1994 May; 54(9):2496-503. PubMed ID: 7909277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
    Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
    Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer.
    Yoshimatsu T; Uramoto H; Oyama T; Yashima Y; Gu C; Morita M; Sugio K; Kohno K; Yasumoto K
    Anticancer Res; 2005; 25(5):3437-43. PubMed ID: 16101161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
    Zhang Z; Ma J; Li N; Sun N; Wang C
    Ann Thorac Surg; 2006 Jul; 82(1):243-8. PubMed ID: 16798222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma.
    Törmänen U; Eerola AK; Rainio P; Vähäkangas K; Soini Y; Sormunen R; Bloigu R; Lehto VP; Pääkkö P
    Cancer Res; 1995 Dec; 55(23):5595-602. PubMed ID: 7585640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
    Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas.
    Mørkve O; Halvorsen OJ; Skjaerven R; Stangeland L; Gulsvik A; Laerum OD
    Anticancer Res; 1993; 13(3):571-8. PubMed ID: 8391242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 expression in non small cell lung cancer: clinical and biological correlations.
    Fontanini G; Bigini D; Vignati S; Macchiarini P; Pepe S; Angeletti CA; Pingitore R; Squartini F
    Anticancer Res; 1993; 13(3):737-42. PubMed ID: 8100413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
    Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
    Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients.
    Ishida T; Kaneko S; Akazawa K; Tateishi M; Sugio K; Sugimachi K
    Cancer Res; 1993 Oct; 53(20):5000-3. PubMed ID: 8104690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung.
    Demarchi LM; Reis MM; Palomino SA; Farhat C; Takagaki TY; Beyruti R; Saldiva PH; Capelozzi VL
    Mod Pathol; 2000 May; 13(5):511-20. PubMed ID: 10824922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neural networks as a prognostic tool for patients with non-small cell carcinoma of the lung.
    Bellotti M; Elsner B; Paez De Lima A; Esteva H; Marchevsky AM
    Mod Pathol; 1997 Dec; 10(12):1221-7. PubMed ID: 9436967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time.
    Ohsaki Y; Toyoshima E; Fujiuchi S; Matsui H; Hirata S; Miyokawa N; Kubo Y; Kikuchi K
    Clin Cancer Res; 1996 May; 2(5):915-20. PubMed ID: 9816250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between survivin expression and prognosis in non-small cell lung cancer.
    Atikcan S; Unsal E; Demirag F; Köksal D; Yilmaz A
    Respir Med; 2006 Dec; 100(12):2220-6. PubMed ID: 16650973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
    Volm M; Koomägi R
    Br J Cancer; 2000 May; 82(10):1747-54. PubMed ID: 10817513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
    Bozcuk H; Gumus A; Ozbilim G; Sarper A; Kucukosmanoglu I; Ozbudak IH; Artac M; Ozdogan M; Samur M; Kaya A; Savas B
    Med Sci Monit; 2005 Jun; 11(6):HY11-20. PubMed ID: 15917726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferating cell nuclear antigen, p53, and c-erbB-2 expression in relation to clinicopathological variables and prognosis in cancer of the ampulla of Vater.
    Ajiki T; Kamigaki T; Hasegawa Y; Fujino Y; Suzuki Y; Takeyama Y; Ku Y; Kuroda Y
    Hepatogastroenterology; 2001; 48(41):1266-70. PubMed ID: 11677943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer.
    Keum JS; Kong G; Yang SC; Shin DH; Park SS; Lee JH; Lee JD
    Br J Cancer; 1999 Sep; 81(1):127-32. PubMed ID: 10487623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.